Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Zebrafish Aid Drug Development

Zebrafish help drug designers sort out structure-activity relationships among candidates

by Sophie L. Rovner
January 25, 2010 | A version of this story appeared in Volume 88, Issue 4

One of the first structure-activity relationship studies in vertebrates confirms that the method can help drug developers zero in on selective small-molecule leads with limited side effects while identifying which leads that look promising in vitro have undesirable in vivo activity (ACS Chem. Biol., DOI: 10.1021/cb9002865). Vanderbilt University’s Charles C. Hong and colleagues performed the study with zebrafish. This tiny fish is an ideal test organism because many experimental drugs can diffuse into its transparent embryo and its development can be monitored for alterations that shed light on a test compound’s bioactivity (C&EN, Sept. 24, 2007, page 103). Hong’s team exposed zebrafish embryos to dorsomorphin, an inhibitor of bone morphogenetic protein (BMP) signaling, which is involved in bone formation and other physiological functions. The assay showed that dorsomorphin also suppresses vascular endothelial growth factor (VEGF) signaling and disrupts angiogenesis. Since both BMP and VEGF are involved in vascular development, the researchers synthesized 63 dorsomorphin analogs to distinguish whether BMP or VEGF affected angiogenesis. DMH1 (shown) inhibited only the BMP pathway and didn’t disrupt angiogenesis, showing that BMP isn’t involved in angiogenesis during development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.